KOLS is 'n kombinasie van 3 verskillende pulmonêre toestande naamlik, kroniese brongitis, asma en emfiseem.
Kroniese brongitis is ’n nonspesifieke obstruktiewe toestand wat gekenmek is deur verhoogde mukussekresie en velaagde mukosilliêre opruiming. Daar sal ook gereelde bakteriële infeksies voorkom. DIt kan herken word deur die verandering in brongiale wande en die persoon sal aanhoudend hoes oor die taai slym in die longe.
Emfiseem word veroorsaak deur rook en irritante. Dit is wanneer die brongioli en aveoli struktureel beskading is en is dus ONomkeerbaar. Die lug word vasgevang en gaswisseling kan nie plaasvind nie, dus sukkel die persoon om die lus weer uit te asem.
Indien die persoon rook, moet hy/sy onmiddelik ophou. Indien daar bakteriële infeksies voorkom sal die persoon antibiotika moet neem. Soms word kortikosteroiede ook bygevoeg saam met ‘n anticholinergiese middel, wat kan help met inflammasie in die longe. Indien die pasiënt slym op die bors het kan ’n verdunning ook geneem word soos ’n ekspektorant wat die slym kan verdun en maklik uit die longe verwyder kan word.
Brongiole asma is gekenmerk deur inflammasie, en Ipratropium is n anticholinergiese mideel wat nie anti-inflammatiese effekte het nie.
Dit help met kontraksie vand ie diafragma en versterk dit. Wat dus kan help met ventilasie en kan hipoksie verminder word.
Indien die middels soos die 2 agoniste of die anticholinergiese middels nie 100% effektief werk nie, moet die pasiënt suurstofterapie kry.
Paracetamol is a weak COX-1 and COX-2 inhibtor and has no anti-inflammtory action, where Aspririn does. It is used in mild to moderate pain when an anti-inflammatory effects if not neccersary.
Used as antipyretic and analgesic agent. It doesn’t affect uric acid levels is not a platelet inhibitor. Used for headache, myalgia, potspartum pain. It is safe to use in pregnancy, children, patients with asthma, gout and patients who have a tendency to bleed easily.
Patients can develop a rash and urticaria.
Within 1-2 days : The patient can become nauseas and vomit, abdominal pain and decreased appetite can occur as well as feeling fatigued.
After 1-2 days : The patient may experience right subcostal pain, jaundice can appear, tar liver and can develop renal insufficiency, liver necrosis and even death.
Treating acute toxicity:
Give a short and critical explanation of the rationale of using fluvoxamine (a selective serotonin reuptake inhibitor (SSRI) in the treatment of Covid patients. Your answer must be properly and appropriately referenced (in-text references as well).
Fluvoxamine is a selective serotonin reuptake inhibitor (SRRI), used in OCD (over compulsive disorder) and depression. In COVID-19 patients Fluvoxamine was found to reduce expression of inflammatory genes. In a study, when SARS-CoV-2 broke out, 65 participant who tested positive opted to take Fluvoxamine and after 14 days the patients who had lower anxiety levels, felt less fatigued and could concentrate better (NIH, 2021:204). Fluvoxamine lowers inflammatory cytokine production. It also has an antiviral effect reducing the ability to enter cells' lysosomes (Lianna Matt Mclemon, 2021:1).
This means that these agents increase intracellular Ca²⁺ in endothelial cells which leads to synthesis of NO. NO diffuses into vascular smooth muscle and leads to vasorelaxation.
Constitutive enzymes are enzymes that are constantly being made whether it is need or not, they also stay is one area, where Inducible enzymes is made when a substance is present. Their effects is smaller.
Sepsis is caused by an infection. Edotoxin components induce synthesis of iNOS in smooth muscle cells, endothelial cells and more, which leads to widespread generation of NO, can lead to hypotension, shock and in some cases death.
Nitric Oxide (NO).
NOS inhibitors are releases which binds to L-arginine form which NO is synthesised from. This prevents arginine to bind to the three NOS enzymes, which leads to decrease concentration of NO.
A Stimulus can activate the inflammatory mediators, which result in increase in iNOS levels. The vasodilatory effects of NO and effects of COX II plays a role in inflammation and causes red skin, increased vascular permeability which can lead to oedema. Although a disadvantage is that excessive production of NO, causes tissue damage, diseases, asthma and lesions.
In stroke, amyotrophic lateral sclerosis, and Parkinson disease, where excessive NO is involved.
Hypertension and cardiac hypertrophy
When angiotensinogen levels increase, more angiotensinogen will be converted to ANG I by renin. ACE converts ANG I to ANG II, which then increase blood pressure, ANG II also increase aldosterone release in the adrenal cortex. ANG II also contribute to cardac hypertrophy which can lead to miocardial infarction which leads to heart failure.
ACE inhibitors, not only inhibit the conversion of ANG to ANG II, but also prevent bradykinin metabolism. Which leads to level of bradykinin increasing, and can acuse side effects like dry cough.
ACE inhibitors works in two ways, 1. Inhibiting the conversion of ANG I to ANG II, and 2. Blocking ANG II type 1 receptors. This causes vasoconstriction, decreasing peripheral resistance and lowering blood pressure. Aldosterone levels decrease, leading to less salt and water retention which decrease CO, cardiac preload and lower blood pressure. ACE inhibitors also prevent bradykinin metabolism which can lead to increased levels of bradykinin and increase arterial vasodilation, lower PR and lowers blood pressure.
Losartan and similar drugs are competitive antagonists at angiotensin AT₁ receptors, but has no effect of angiotensin 2 receptors.
Kinins produce arteriolar dilation which is an effect of kinins on arteriolar smooth muscle mediated by nitrite oxide of vasodilation prostaglandins. Kinins causes contraction in veins due to contraction in visceral smooth muscle.
Bradykinin 2 receptors.
Natriuretic peptides causes vasodilation that leads to decrease in PR and lowers blood pressure in patients with hypertension. These peptides also increase glomerular filtration which leads to more sodium excretion and decreasing sodium reabsorption, thus treating oedema that is associated with congestive heart failure.
Neprilysin metabolises natriuretic peptides, inhibiting Neprilysin leading vasodilation of ANP and BNP level increase and increase in renin secretion leading to higher levels of ANG II, helping in treatment of heart failure.
Drug name: Sacubitril
Vasodilators: Bosentan, macitentan, ambrisentan, sitaxsentan.
Vasoconstrictors: Endothelin 1,2,3
Migraine involves the trigeminal nerve distribution to intracranial arteries. These nerves release neurotransmitters like calcitonin (a vasodilator). The vasodilation and stretching caused by perivascular edema may be the cause of migraine. Relieve of a migraine can be by therapy of diminution of these pulsations.
Sumatriptan is first in line to treat acute severe migraine, because it’s a generic and much cheaper than the other -triphans, and should not be used in patients with coronary artery disease because it can cause discomfort and pain in chest. Anti-inflammatory anagelsics such as Aspirin and Ibuprofen can also be used. For patients with severe nausea and vomiting, can parenteral Metoclopramide be used. Almotriptan, Rizatriptan and Zolmitriptan can also be used but they do have a short duration of effect. Naratriptan and Eletriptan, Frovatriptan and Zolmitriptan can also be used but have some contraindications.
Lasmiditan is also used for antimigraine. It has the affinity for 5-HT receptors, it does not cause vasoconstriction and is thus safer than triptans regarding cardiovascular system. It reduces trigeminal nerve stimulation-induces plasma and plasma protein extravasation in dural vessels. Erenumab and Ubrogepant binds to CGRP receptors and prevents activation by peptides, and treat acute migraine attacks. Propanalol, Amitriptyline and some Ca²⁺ blockers can also be used in migraines. Flunarizine (Ca²⁺ blocker) reduce the severity of an acute attack. Verapamil have also been effective.